Urogen Pharma Ltd. (URGN) Stock Price & Analysis
Urogen Pharma Ltd. (URGN) fell 1.76% to USD 44.09 as of September 8, 2026 at 10:15 UTC, according to Nexqual real-time market data.
URGN last closed at USD 44.09; the session ranged USD 43.51–45.1 on volume of 779,042 shares. Market capitalization is —, with a 52-week range of USD 15.86–50.81 (NGM). Source: Nexqual, September 8, 2026 at 10:15 UTC.
Key Statistics (as of September 8, 2026 at 10:15 UTC)
| Price | USD 44.09 |
|---|---|
| Change | ▼ 1.76% (down) |
| Previous Close | USD 44.09 |
| Open | USD 44.09 |
| Day Range | USD 43.51 – 45.1 |
| 52-Week Range | USD 15.86 – 50.81 |
| Volume | 779,042 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (URGN)
Nexqual's technical model rates URGN "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 10:15 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 45.21 (neutral) |
| vs SMA50 | Above (USD 42.65) |
| MACD | 0.38 (positive) |
From Urogen Pharma Ltd.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Serious adverse reactions occurred in 12% of patients who received  Zusduri , including, urinary retention (0.8%) and urethral stenosis (0.4%).   As a post-marketing commitment, we have agreed with the FDA to complete the ongoing ENVISION trial to further characterize the clinical benefit of  Zusduri  for the treatment of adult patients with recurrent low-grade intermediate risk NMIBC.
- Furthermore, we believe our proprietary formulation technology has broad applications and may allow us to develop additional product candidates for indications within and beyond the urinary tract.   9 Table of Contents   Potential ability to develop additional minimally invasive, drug therapies for uro-oncology .
- Furthermore, Jelmyto has received Orphan Drug Designation from the FDA for the treatment of low-grade UTUC, which provides seven years of regulatory exclusivity following FDA approval.   Leverageable proprietary formulation technology.
- We have developed  RTGel  reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs.
Partnerships
- In November 2025, we provided notice to terminate the license agreement with Agenus in connection with our decision to discontinue development of UGN-301.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANAB | AnaptysBio, Inc. | USD 56.8 | ▲ 1.72% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 102.74 | ▼ 2.54% |
| REPL | Replimune Group, Inc. | USD 15.04 | ▼ 5.88% |
| SNDX | Syndax Pharmaceuticals, Inc. | USD 20.56 | ▼ 1.06% |
| PHAT | Phathom Pharmaceuticals, Inc. | USD 9.5 | ▲ 2.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:15 UTC. This page is informational and not investment advice.